SCHEMBL29409061

SCHEMBL29409061

CC(C)(C)OC(=O)NC12CC(n3cnc(-c4ccc(Cl)c(F)c4)c3)(C1)C2

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 6/20 0.47
▸ KMO O15229 2/20 0.39
▸ ABL1 P00519 1/20 0.36
▸ KAT8 Q9H7Z6 3/20 0.36
▸ IDO1 P14902 1/20 0.35
▸ DPP8 Q6V1X1 1/20 0.35
▸ DPP9 Q86TI2 1/20 0.35
▸ AAK1 Q2M2I8 2/20 0.35
▸ GSK3B P49841 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.34
▸ EGLN2 Q96KS0 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29408935 0.91 DPP8 (0.38) ATF4KMOKAT8IDO1DPP8
SCHEMBL29499485 0.91 DPP8 (0.38) ATF4KMOKAT8IDO1DPP8
SCHEMBL29409230 0.87 DRD2 (0.39) ATF4IDO1GSK3BDYRK1A
SCHEMBL29409165 0.86 ATF4 (0.42) ATF4IDO1DPP8DPP9GSK3B
SCHEMBL29591264 0.85 ATF4 (0.41) ATF4KAT8IDO1DPP8DPP9
SCHEMBL22614106 0.85 ATF4 (0.48) ATF4KMOABL1KDM4CEGLN2
SCHEMBL29590644 0.84 ATF4 (0.44) ATF4KMOABL1IDO1DPP8
SCHEMBL29592358 0.83 ATF4 (0.40) ATF4KMOIDO1DPP8DPP9
SCHEMBL29499492 0.82 GSK3B (0.37) ATF4IDO1DPP8DPP9GSK3B
SCHEMBL29409171 0.82 GSK3B (0.37) ATF4IDO1DPP8DPP9GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2025-05-08 — — US disclosed
EP-4237413-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2023-09-06 — — EP disclosed
WO-2022094244-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-05-05 — — WO disclosed
CN-114206848-A Substituted cycloalkyl compounds as modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-03-18 — — CN disclosed
EP-3962906-A1 SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2022-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 ATF4 1/4885KMO 2788/4885ABL1 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback